Shares of Novo Nordisk (NVO) fell as much as 7% on Monday after the company presented its long-term growth strategy to investors, which failed to alleviate concerns about intensified competition in the obesity drug market. The decline follows a broader selloff in the company’s stock, which has dropped more than 70% since its mid-2024 peak. The company’s shares closed at $40.26, down 5% from the previous day, while the broader health care sector saw only a slight decline, indicating the selloff was company-specific rather than sector-wide.
Novo Nordisk’s strategic update included plans to launch more than five new blockbuster drugs by 2030 and generate over 150 billion Danish kroner ($23 billion) in pipeline sales by 2035. The company also aims to reach more than 60 million patients globally by 2030 and scale up manufacturing to supply 15 million patients with oral obesity therapies by 2030. Despite these ambitions, investors remained skeptical, citing concerns over patent expirations for semaglutide, the active ingredient in its blockbuster drugs Wegovy and Ozempic, which are set to expire in the early 2030s.
Part 1: Immediate Action & Core Facts
Novo Nordisk’s stock decline and strategic update: Novo Nordisk’s shares fell 7% after the company outlined its long-term growth strategy, which included plans to launch multiple new blockbuster drugs and generate $23 billion in pipeline sales by 2035. The company also aims to scale up manufacturing and reach 60 million patients globally by 2030.
Investor skepticism and competitive pressure: Investors expressed concerns over Novo Nordisk’s ability to defend its market position amid rising competition from rivals such as Eli Lilly, whose drugs Mounjaro and Zepbound have gained significant market share. The company’s stock decline was isolated, with the broader health care sector seeing only a slight drop, indicating the selloff was company-specific.
Part 2: Deeper Dive & Context
Company’s strategic response to competition
Novo Nordisk’s CEO Mike Doustdar acknowledged the intensified competition, stating that the company now faces competition from "almost every other single pharma company, big or small," a stark contrast to its historical duopoly in the market. Doustdar emphasized the need to prepare for this new competitive landscape, including investing more aggressively in research and development to address future patent expirations.
The company also announced plans to cut 13,000 jobs over the past year, including 9,000 layoffs and 4,000 unfilled positions that were not replaced, as part of its cost-cutting measures to navigate the competitive environment. Doustdar has been focused on improving the marketing of Wegovy and building momentum behind its oral obesity therapy, which has underperformed analyst estimates in recent quarters.
Market reaction and broader implications
While Novo Nordisk’s stock decline was significant, the broader health care sector saw only a slight drop, with the Health Care Select Sector SPDR ETF (XLV) down 0.4%, confirming the selloff as company-specific rather than sector-wide. Rival Eli Lilly’s stock slipped 0.7%, while Viking Therapeutics (VKTX) saw a 1% increase, reflecting investor rotation toward next-generation obesity drug competitors.
Analysts have noted that Novo Nordisk’s long-term growth ambitions are ambitious but lack immediate catalysts to reassure investors. Derren Nathan, head of equity research at Hargreaves Lansdown, stated that the company’s plans "look more like a strategic roadmap than a fresh clinical or commercial catalyst," adding that Eli Lilly’s stronger near-term pipeline momentum has given it a competitive edge in the obesity drug market.
Patent expirations and future challenges
Novo Nordisk faces a significant challenge with the 2032 U.S. patent expiry for semaglutide, the active ingredient in Wegovy and Ozempic, which currently drive over half of the company’s annual sales. The company is racing to develop new drugs and expand its pipeline to mitigate the impact of these patent expirations. Doustdar has emphasized the importance of overcoming these challenges to sustain the company’s growth trajectory.
Industry outlook and patient behavior shifts
The obesity drug market remains a high-growth sector, with patients increasingly behaving like consumers in their treatment choices. Analysts note that the market still has "plenty of runway," but Novo Nordisk’s ability to maintain its leadership position will depend on its ability to innovate and compete effectively against rivals like Eli Lilly and emerging competitors.